Everlywell (Weight Care+) Review
Appears to have shut downEverlywell (Weight Care+)'s strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the plan
Medication
Charged on top
Clinician visits
In the price
Shipping
Charged on top
Lab work
Not stated
Coaching
Not stated
Everlywell (Weight Care+) is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
See our top-rated GLP-1 providers →Membership runs 99 dollars per month on a 12-month commitment or 139 dollars per month on a 3-month one. That fee buys ongoing virtual clinician consults, GLP-1 prescriptions written and renewed, and insurance navigation. Everlywell does not sell the medication itself: brand-name prescriptions such as Wegovy, Ozempic or Zepbound go to a pharmacy of your choice and are billed there, roughly 900 to 1,400 dollars per month in cash or an insurance copay. Weight Care+ comes from the established at-home lab and health brand.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Everlywell (Weight Care+)
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Everlywell (Weight Care+) at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $99/mo (Program membership fee only (12-mo commit; 139/mo on 3-mo). Brand medication billed separately at your pharmacy, roug...)
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Consult
- FDA status
- No FDA warning letter on record
How Everlywell (Weight Care+) scores
Six columns, each one computed from something Everlywell (Weight Care+) has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10The figures published here are not comparable monthly cash prices for the medication — an insured copay, a per-vial rate, a membership fee or a starting-dose teaser. Capped rather than scored against the register.
Effectiveness25%
9.0/10Dispenses semaglutide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
6.5/10does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
2.5/10The price covers consult.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Everlywell (Weight Care+)
Last checked July 2026- Re-read the price on file across 1 dose or plan tier
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with Everlywell (Weight Care+) involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Everlywell (Weight Care+) publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Everlywell (Weight Care+) does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering consult.
- No comparable monthly cash price for the medication is on record — either nothing is published, or what is published is a fee, an insured copay or a per-vial rate rather than a monthly cost.
- No state list is published, so whether Everlywell (Weight Care+) serves your state cannot be confirmed from its site.
GLP-1 medications Everlywell (Weight Care+) offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Program membership fee only (12-mo commit; 139/mo on 3-mo). Brand medication billed separately at your pharmacy, roughly 900-1400/mo cash or insurance copay
Check the price yourself before you pay
Every figure here was read off Everlywell (Weight Care+)'s own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers consult
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- Billed separately from the monthly figure: medication, shipping
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
What Everlywell (Weight Care+) charges
Everlywell (Weight Care+) does not publish a standing monthly price. That is a choice, and it means you cannot compare it against anything until you have gone through an intake and been quoted. When you get that quote, ask specifically for the ongoing monthly figure and what it includes — not the first-month rate, and not a program total divided by its length.
What Everlywell (Weight Care+) dispenses
Everlywell (Weight Care+) prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them. These are FDA-approved brand-name products rather than compounded preparations, which is the more expensive route and the one where what is in the vial has been reviewed.
What we could verify
Everlywell (Weight Care+) publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You need to compare prices before committing time to an intake — there is no published figure to compare.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- you want the price to stop moving as your dose climbs
Our read
We cannot tell you whether Everlywell (Weight Care+) is priced well, because it does not say. That is not automatically disqualifying — plenty of legitimate operators quote after intake — but it does mean the comparison has to happen after you have spent the time, which is the wrong order for the buyer. CoreAge Rx is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
Everlywell (Weight Care+)'s strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Everlywell (Weight Care+) review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.